Sensitive Cloud Point Extraction Methodology for Separation Preconcentration of Co(II) Followed by Spectrophotometric Determination in Different Samples

With application CPE methodology to separation preconcentration and extraction Co2+ion used 2-[4-antybyren zolylazo]-1,2-dihydroxy-9,10-anthracene-dione (AADAD) as complexing agent to form ion pair complex as well as used non-ionic surfactant 1% Tritonx-100 at PH=8 , also this research involved limitation optimum conditions as well as thermodynamic study , Synergism effect and spectrophotometric determination of Co(II) in different samples with detection limit(D.L) =(1.6559×10-5µg.mL-1) and Sandell’s sensitivity =(7.99×10-5mg.cm-2) and ε =(7374.12L.mol-1.cm-1 )and RSD% =(%0.0065). Keywords:Cobalt(II) , Cloud point layer ,TritonX-100

Selective suprasensitivity to calcitonin-gene-related peptide in the hands in Raynaud's phenomenon

Original article can be found at:http://www.sciencedirect.com/science/journal/01406736 Copyright Elsevier Ltd. [Full text of this article is not available in the UHRA]The effects of intravenous infusion of three vasodilators on skin blood flow were studied in eight patients with Raynaud's phenomenon and eight controls, matched for age and sex, by means of the non-invasive technique of laser doppler flowmetry (LDF). The responses to calcitonin-gene-related peptide (CGRP) were compared with those to the endothelium-dependent vasodilator adenosine triphosphate (ATP) and the endothelium-independent vasodilator prostacyclin (epoprostenol; PGI2). In the patients with Raynaud's phenomenon, CGRP induced flushing of the face and hands accompanied by a rise in skin blood flow, whereas in the controls CGRP caused flushing and increased blood flow only in the face. PGI2 caused similar rises in skin blood flow in the hands and face in both groups. ATP did not cause any significant changes in skin blood flow in the face or hands in the patients, but in the controls it increased skin blood flow in the face. Since the suprasensitivity to CGRP of skin blood flow in the hands of patients with Raynaud's phenomenon is not common to other vasodilators, it may reflect a deficiency of endogenous CGRP release in this disorder.Peer reviewe

Prolonged effect of CGRP in Raynaud's patients : a double-blind randomised comparison with prostacyclin

Original article can be found at: http://www.ncbi.nlm.nih.gov/pmc/issues/127390/ Copyright British Pharmacological Society. [Full text of this article is not available in the UHRA]1. Calcitonin gene related peptide (CGRP) is a potent endogenous vasodilator to which we have previously demonstrated a specific hypersensitivity in skin blood flow in the hands in patients with Raynaud's disease. 2. We have now investigated whether long infusion of CGRP can relieve symptoms of patients with Raynaud's disease using prostacyclin as a control. 3. Six patients were randomised to receive intravenous infusion of either human alpha-CGRP on one occasion, or prostacyclin (PGI2) on another occasion in a double-blind and cross-over design. The dose of each agent was initially titrated up to 8 ng kg-1 min-1 or to a maximum increase in heart rate of 25 beats min-1. 4. In addition to blood pressure, heart rate and skin blood flow measurements, infrared thermography and cold stress challenge was performed before, immediately after infusion and at 3 and 14 days post-infusion. 5. CGRP caused an increase in hand skin blood flow throughout its infusion, whilst PGI2 caused only a short lived increase. The thermographic results showed significant improvement in hand rewarming 3 days after CGRP but not after PGI2. 6. We conclude that 3 h infusion of CGRP was better tolerated than PGI2 and caused objective improvement up to 3 days. CGRP may be an alternative to PGI2 in some patients.Peer reviewe